Back HIV/Hepatitis Coinfection

Coinfection

HCV Does Not Worsen Cognitive Impairment in HIV Positive People without Advanced Liver Damage

Coinfection with hepatitis C virus (HCV) does not appear to contribute to neurocognitive impairment in people with HIV who do not have advanced liver disease, according to results from the CHARTER study published in the December 10 online edition of Neurology.

alt

Read more:

IDWeek 2014: HIV and Hepatitis B Coinfection Linked to Hip Fractures

People with HIV/HBV coinfection being treated for both diseases had a significantly higher risk of hip fractures than patients with HIV alone or neither virus, according to research presented at IDWeek 2014 last week in Philadelphia.

alt

Read more:

AIDS 2014: AbbVie 3D Regimen Cures Most Genotype 1 HIV/HCV Coinfected Patients

An all-oral regimen of 3 direct-acting antivirals plus ribavirin taken for 12 weeks demonstrated a sustained virological response rate of 94% for people coinfected with HIV and genotype 1 hepatitis C in the TURQUOISE-I study, according to a late-breaking report at the 20th International AIDS Conference (AIDS 2014) this week in Melbourne, Australia.

alt

Read more:

IDWeek 2014: Study Shows HIV/HCV Coinfected Women Have Lower Bone Density

ART-treated women with HIV/HCV coinfection have greater deficits in some structural bone parameters compared to women with HIV only, HCV only, or neither virus, according to the results of a cross-sectional study presented at IDWeek 2014 last week in Philadelphia. Among women with HCV, bone loss was most profound in those with stage 3-4 liver fibrosis or cirrhosis, which adversely effects bone health.

alt

Read more:

AIDS 2014: Sofosbuvir + Ribavirin Cures More Than 80% of HIV/HCV Coinfected People

An interferon-free regimen of sofosbuvir (Sovaldi) plus ribavirin for 24 weeks led to sustained virological response in 84% to 89% of HIV positive chronic hepatitis C patients with HCV genotypes 1, 2, 3, or 4, according to results from the PHOTON-2 study presented at the 20th International AIDS Conference in Melbourne, Australia. Cure rates were lower, however, for genotype 1a patients with liver cirrhosis.

alt

Read more:

IDWeek 2014: HIV/HCV Coinfected People Do Not Have Poorer CD4 Cell Recovery

Among HIV positive people on suppressive antiretroviral therapy (ART), hepatitis C virus (HCV) coinfection was not associated with significantly lower CD4 T-cell or B-cell gains, according to study findings presented at IDWeek 2014 last week in Philadelphia.alt

Read more:

Tenofovir Usually Suppresses Hepatitis B in HIV/HBV Coinfected People

Tenofovir led to undetectable hepatitis B virus (HBV) levels in 87% of HIV positive coinfected individuals, and a similar proportion maintained viral suppression over 6 years, according to a study described in the June 20 advance edition of Hepatology.

alt

Read more:

AIDS 2014: HIV/HCV Coinfected Have High Cure Rates with Interferon-free Hep C Combos

Two studies presented at the 20thInternational AIDS Conference this week in Melbourne showed that all-oral regimens of direct-acting antiviral agents for hepatitis C are safe and effective for HIV positive people. Both regimens demonstrated sustained virological response rates similar to those seen in people with HCV alone.

-- Sofosbuvir + Ribavirin Cures More Than 80% of HIV/HCV Coinfected People

-- AbbVie 3D Regimen Cures Most Genotype 1 HIV/HCV Coinfected Patients

alt

Read more:

DDW 2014: Outcomes in HBV/HCV Coinfected People Depend on Which Virus Dominates

Among HBV/HCV coinfected people, about half have dominant hepatitis B virus while half have dominant hepatitis C, and those with active HBV replication are at higher risk of liver-related complications and death, according to study findings presented at Digestive Disease Week this month in Chicago.

alt

Read more: